

**Supplementary Table 1****Clinical data of the TREMEND trial before and after treatment with DMF**

<b>Clinical data</b>	<b>Values</b>
Number of days from relapse to initiation of DMF ( $\pm$ SD)	108.9 ( $\pm$ 104.6)
Number of patients with new/enlarging T2 lesions during year 1 (%)	13/52 (25.0)
Number of patients with relapses during year 1 (%)	11/52 (21.2)
Number of patients with relapses during year 2 (%)	9/52 (17.3)
EDSS at baseline ( $\pm$ SD)	1.73 ( $\pm$ 0.84)
EDSS after 1 year ( $\pm$ SD)	1.56 ( $\pm$ 0.76)
EDSS after 2 years ( $\pm$ SD)	1.64 ( $\pm$ 0.77)

DMF: dimethyl fumarate; EDSS: Expanded Disability Status Scale; SD: standard deviation